technology
Startup 10x Science Raises $4.8 Million to Analyze AI-Generated Drug Candidates
10x Science, a startup founded in December 2025, announced a $4.8 million seed funding round to develop a platform for characterizing potential drug candidates generated by AI models. The platform uses algorithms and AI to interpret mass spectrometry data for biologic drugs. Founders aim to address bottlenecks in drug development by providing traceable analyses for regulatory compliance.
TE
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
A startup called 10x Science has raised $4.8 million in seed funding to build a platform that analyzes potential drug candidates produced by AI models. The company was founded in December 2025 by three individuals with backgrounds in biochemistry, computer science, and AI.
The funding round was led by Initialized Capital, with participation from Y Combinator, Civilization Ventures, and Founder Factor. The platform focuses on characterizing proteins for biologic drugs, which are produced in living cells and target specific diseases.
The founders previously worked in a Stanford lab studying cancer cell and immune system interactions. They identified challenges in understanding molecular structures using mass spectrometry, a technique that measures molecules in an electric field to determine atomic structure.
The platform combines deterministic algorithms with AI agents to interpret this data, ensuring traceability for regulatory purposes. A scientist at Rilas Technologies, which provides chemical analyses for biotech firms, has used the platform for several weeks.
The scientist reported that it speeds up work by explaining conclusions, searching databases independently, and adapting to different molecules. For example, the system identified a protein sequence from a file name and retrieved relevant data without manual input.
“I ran a particular protein through it, and it just kind of figured out, from what I named the file, what the protein probably was," Crawford said. The seed funding will support hiring engineers and refining the model for new customers. The company plans to expand beyond protein characterization to integrate additional cellular data for broader biological insights. Investors view the platform as a recurring revenue tool for the pharmaceutical industry, independent of specific drug approvals. A partner at Initialized noted the founders' expertise as a barrier to competition. The platform aims to assist researchers lacking resources for advanced spectrometry by providing quick, accurate analyses.”
